Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Zimmer Biomet Holdings Inc. (ZIM.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
113.10-0.14 (-0.12%)
At close: 08:04AM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close113.24
Open113.10
Bid113.36 x 50000
Ask115.62 x 50000
Day's Range113.10 - 113.10
52 Week Range95.04 - 123.38
Volume0
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 06, 2023 - Feb 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Zimmer Biomet to Present at the 34th Annual Piper Sandler Healthcare Conference

    Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Executive Management Team will present at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 2:00 p.m. Eastern Time.

  • PR Newswire

    Zimmer Biomet Expands Persona® Knee System Portfolio with FDA Clearance of Persona® OsseoTi® Keel Tibia for Cementless Knee Replacement

    Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Persona® OsseoTi® Keel Tibia for cementless knee replacement. Persona OsseoTi is the latest addition to the clinically proven Persona Knee System, and features a new porous version of the Persona anatomic tibia with Zimmer Biomet's OsseoTi Porous Metal Technology, which uses anatomical data in combination with 3D printing technolog

  • PR Newswire

    Zimmer Biomet Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting

    Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced one-year data from a multicenter, prospective, randomized controlled trial to evaluate the impact of mymobility® with Apple Watch, a first-of-its-kind remote care management platform. The data show that using mymobility with Apple Watch following primary knee arthroplasty, commonly known as knee replacement, can effectively guide rehabilitation, demonstrate similar outcomes to traditional care m

Advertisement
Advertisement